Evidence map›Paper›PMID 40685563›Full record

ArticleAlimentary pharmacology & therapeutics2025

Clinical and Genetic Associations in Cephalosporin-Induced Liver Injury: Insights From the Drug-Induced Liver Injury Network.

Raj Vuppalanchi, Yi-Ju Li, Don C Rockey, Dina Halegoua-DeMarzio, Robert J Fontana, Herbert L Bonkovsky, Christopher Koh, Joseph Odin, Huiman Barnhart, Jay H Hoofnagle and 1 more

Abstract read
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Common Causes of Drug-Induced Liver Injury in 2025.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  2. Article
  3. [Research progress in the field of drug-induced liver injury in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raj VuppalanchiIndiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-0637-1577
Yi-Ju LiDuke University School of Medicine, Durham, North Carolina, USA.
Don C RockeyMedical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0002-3751-2961
Dina Halegoua-DeMarzioSidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Robert J FontanaUniversity of Michigan, Ann Arbor, Michigan, USA.
Herbert L BonkovskyAtrium Health Wake Forest Baptist and Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Christopher KohNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-4755-5607
Joseph OdinIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Huiman BarnhartDuke University School of Medicine, Durham, North Carolina, USA.
Jay H HoofnagleNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Drug‐Induced Liver Injury Network (DILIN)

Funding

Drug Induced Liver Injury Network Data Coordinating CenterU01DK065176 · NIDDK · DUKE UNIVERSITY · PI Huiman X Barnhart · 2003 to 2026
$25.5M
Coordinating Center for the Drug Induced Liver Injury Network (DILIN)U24DK065176 · NIDDK · DUKE UNIVERSITY · PI BARNHART, HUIMAN X · 2018 to 2022
$7.6M
IU Clinical Center: Drug Induced Liver Injury NetworkU01DK065211 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI NAGA P CHALASANI · 2003 to 2026
$7.5M
University of North Carolina Clinical Center for DILINU01DK065201 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAUL B WATKINS · 2003 to 2026
$7.3M
Michigan Hepatotoxicity Clinical Research Network Renewal 2018U01DK065184 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROBERT J FONTANA · 2003 to 2026
$7.0M
The Drug Induced Liver Injury Network (DILIN): Focus on Herbal and DietarySupplementsU01DK083027 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI Dina Halegoua-DeMarzio · 2008 to 2026
$7.0M
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.U01DK083020 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Lily Dara · 2008 to 2026
$5.9M
NIDDK NIH HHS U01 DK065176NIDDK NIH HHS U01 DK065184NIDDK NIH HHS U01DK065184NIDDK NIH HHS U01 DK065201NIDDK NIH HHS U01DK065201NIDDK NIH HHS U01 DK065211NIDDK NIH HHS U01DK065211NIDDK NIH HHS U01 DK083020NIDDK NIH HHS U01DK083020NIDDK NIH HHS U01 DK083027NIDDK NIH HHS U01DK083027NIDDK NIH HHS U24 DK065176NIDDK NIH HHS U24DK065176
6 · The paper itself

Abstract

introductionCephalosporins are widely prescribed antibiotics due to their efficacy and safety. Although rare, idiosyncratic drug-induced liver injury (DILI) has been reported with their use. Here, we characterise the clinical features and HLA associations of cephalosporin-related liver injury.

methodsBetween Jan 1, 2004, and Nov 2, 2022, a total of 2347 cases of DILI were enrolled in the DILIN study, of which 1854 were adjudicated as probable, highly likely, or definite. HLA sequencing was performed, and association with the risk of DILI was examined.

results58 cases (3%) were attributed to different cephalosporins, including cefazolin (n = 40), cephalexin (n = 4), ceftriaxone (n = 3), cefdinir (n = 3), cefuroxime (n = 3), and five other individual agents. Clinical features included a self-limited course with a mixed or cholestatic biochemical pattern without hypersensitivity features occuring in 1 to 4 weeks. Most striking was the phenotype of cefazolin and other parenteral cephalosporins given as a single dose with the onset of jaundice, fatigue, and itching 1 to 3 weeks later. In the total cohort, HLA-A*02:01 was significantly associated with an increased risk of cephalosporin-induced liver injury (OR: ~2.5-2.7, P < 0.0001). The association was strongest with cefazolin, with carrier frequencies of 85% vs. 38% in those with DILI from other drugs.

conclusionsCephalosporins can cause self-limited, mixed/cholestatic hepatitis that arises after a short course of therapy with a latency of up to 3 weeks with cefazolin. Cephalosporin-induced liver injury is associated with the HLA-A*02:01 allele, which is linked to more severe liver injury at the onset of illness.

Indexed as

Anti-Bacterial AgentsCephalosporinsChemical and Drug Induced Liver InjuryAdultAgedFemaleHumansMaleMiddle AgedAnti-Bacterial AgentsCephalosporinsantibioticscefazolindrug‐induced liver injuryhepatotoxicity

Identifiers

PMID40685563
PMCPMC12543336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.